Our data support a cell therapy strategy for eradicating tumors [37]; a patient’s tumor-presented MHCI-neoantigens can be co-cultured with isolated PBMCs in vitro to activate CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.